For moderate to severe Crohn's disease (CD) or moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients.1
ONCE DAILY
IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor
RINVOQ IS A ONCE-DAILY PILL
THAT COMES IN THREE DOSAGE STRENGTHS
One strength for induction and two strengths for maintenance1
Images not reflective of actual pill size.
CD INDUCTION DOSE:
12 WEEKS
The recommended induction dose of RINVOQ is 45 mg once daily for 12 weeks.
Images not reflective of actual pill size.
Images not reflective of actual pill size.
CD MAINTENANCE DOSE
The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily.
A maintenance dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dose.
Use the lowest effective dosage needed to maintain response.
ADMINISTRATION
Instruct patients to take 1 pill, once daily.1
Ensure pill is taken whole. Do not split, crush, or chew.1
RINVOQ can be taken with or without food. Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ.1
MEDICATION
RESIDUE IN STOOL
Instruct patients to notify their healthcare provider if they repeatedly notice intact RINVOQ tablet or fragments in stool or ostomy output.
Limitations of Use for CD: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn's disease, or with potent immunosuppressants such as azathioprine and cyclosporine.
Limitations of Use for CD: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with potent immunosuppressants such as azathioprine and cyclosporine.
Images not reflective of actual pill size.
UC INDUCTION DOSE:
8 WEEKS
The recommended induction dose of RINVOQ is 45 mg once daily for 8 weeks.
Images not reflective of actual pill size.
Images not reflective of actual pill size.
UC MAINTENANCE DOSE
The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily.
A maintenance dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dose.
Use the lowest effective dosage needed to maintain response.
ADMINISTRATION
Instruct patients to take 1 pill, once daily.1
Ensure pill is taken whole. Do not split, crush, or chew.1
RINVOQ can be taken with or without food. Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ.1
MEDICATION
RESIDUE IN STOOL
Instruct patients to notify their healthcare provider if they repeatedly notice intact RINVOQ tablet or fragments in stool or ostomy output.
Limitations of Use for UC: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn's disease, or with potent immunosuppressants such as azathioprine and cyclosporine.
Limitations of Use for UC: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine
LAB MONITORING
AND
DOSING
CONSIDERATIONS1
Perform lab testing for:
INTERRUPT IF PATIENT DEVELOPS A SERIOUS OR OPPORTUNISTIC INFECTION.
*Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.1
INTERESTED IN LEARNING MORE
ABOUT THE SAFETY DATA?
See RINVOQ’s safety data
across clinical trials
